Anzeige
Mehr »
Login
Montag, 27.01.2020 Börsentäglich über 12.000 News von 622 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JRLW ISIN: US74374N1028 Ticker-Symbol: 2VB 
Frankfurt
24.01.20
18:46 Uhr
14,500 Euro
+0,200
+1,40 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PROVENTION BIO INC Chart 1 Jahr
5-Tage-Chart
PROVENTION BIO INC 5-Tage-Chart
RealtimeGeldBriefZeit
14,422
14,566
26.01.

Aktuelle News zur PROVENTION BIO Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PROVENTION BIO Aktie jetzt für 4€ handeln
MiNew hires at bluebird bio, BioNTech and Provention Bio65
08.01.Provention Bio, Inc. - 8-K, Current Report4
03.01.J&J drops its option on Provention Bio drug after trial failure8
03.01.After midstage flop, Janssen says thanks but no thanks to Provention Bio drug2
26.12.19Provention Bio, Inc. - 8-K, Current Report1
12.12.19Provention Bio reaffirms PRV-031 application timeline; shares up 5% premarket5
29.11.19Provention Bio: The Time Is Right For Teplizumab - High Potential Upside, Low Valuation, Milestones Approaching4
09.11.19Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2019 Results - Earnings Call Transcript5
05.11.19Provention Bio EPS beats by $0.056
05.11.19Provention Bio, Inc. - 10-Q, Quaterly Report1
28.10.19Provention Bio wins PRIME designation for type 1 diabetes prevention drug1
25.10.19Provention Bio's diabetes drug gains PRIME status; Avrobio earns orphan status2
23.10.19Provention Bio's J&J-licensed Crohn's drug stumbles in mid-stage study3
22.10.19Provention Bio's Phase 2a Study On Crohn's Disease Fails To Meet Primary Goal-
22.10.19Provention Bio down 9% premarket on PRV-6527 flop1
09.10.19Five Prime Therapeutics leads healthcare gainers; Provention Bio tops the losers9
03.10.19Provention Bio Is A Misunderstood Biotech With A Potential Quick Pathway To FDA Approval For Type 1 Diabetes Treatment2
30.09.19Provention Bio, Inc. - 8-K, Current Report-
24.09.19Provention Bio up 6% premarket on development plan for teplizumab1
19.09.19Provention Bio, Inc. - 8-K, Current Report-
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1